Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$132.63
-0.4%
$126.93
$110.04
$238.00
$19.47B0.141.44 million shs633,328 shs
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$109.65
+1.3%
$102.74
$76.53
$131.49
$26.44B1.29944,276 shs613,718 shs
Moderna, Inc. stock logo
MRNA
Moderna
$30.47
+0.6%
$26.72
$23.15
$129.39
$11.79B1.848.72 million shs6.97 million shs
Novozymes A/S stock logo
NVZMY
Novozymes A/S
$70.91
-1.0%
$70.07
$53.95
$75.99
$33.21B0.9115,224 shs23,920 shs
Seagen Inc. stock logo
SGEN
Seagen
$228.74
$228.74
$123.77
$228.96
$42.93B0.321.48 million shs86 shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
0.00%+5.19%+1.74%+7.84%-40.95%
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.00%+2.74%-0.46%+24.53%+37.30%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%+12.19%+16.65%+21.35%-73.72%
Novozymes A/S stock logo
NVZMY
Novozymes A/S
0.00%-1.96%-1.06%+16.42%+14.69%
Seagen Inc. stock logo
SGEN
Seagen
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biogen Inc. stock logo
BIIB
Biogen
4.9303 of 5 stars
4.25.00.03.73.21.71.9
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.3272 of 5 stars
4.42.00.00.01.10.80.0
Moderna, Inc. stock logo
MRNA
Moderna
4.3793 of 5 stars
4.02.00.04.61.32.50.6
Novozymes A/S stock logo
NVZMY
Novozymes A/S
N/AN/AN/AN/AN/AN/AN/AN/A
Seagen Inc. stock logo
SGEN
Seagen
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biogen Inc. stock logo
BIIB
Biogen
2.38
Hold$188.4842.12% Upside
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.83
Moderate Buy$137.8625.73% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$46.6152.97% Upside
Novozymes A/S stock logo
NVZMY
Novozymes A/S
3.00
BuyN/AN/A
Seagen Inc. stock logo
SGEN
Seagen
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest BIIB, SGEN, MRNA, BNTX, and NVZMY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Biogen Inc. stock logo
BIIB
Biogen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$187.00
6/25/2025
Biogen Inc. stock logo
BIIB
Biogen
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$205.00 ➝ $213.00
6/25/2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$138.00
6/16/2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$145.00 ➝ $138.00
6/12/2025
Biogen Inc. stock logo
BIIB
Biogen
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$115.00
6/12/2025
Biogen Inc. stock logo
BIIB
Biogen
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$121.00
6/12/2025
Biogen Inc. stock logo
BIIB
Biogen
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
6/5/2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$134.00 ➝ $145.00
6/3/2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$151.00 ➝ $155.00
6/2/2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$112.00
6/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biogen Inc. stock logo
BIIB
Biogen
$9.68B2.01$23.07 per share5.75$114.71 per share1.16
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$2.98B8.85N/AN/A$87.61 per share1.25
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.64N/AN/A$28.33 per share1.08
Novozymes A/S stock logo
NVZMY
Novozymes A/S
$4.15B8.00$1.86 per share38.18$25.82 per share2.75
Seagen Inc. stock logo
SGEN
Seagen
$2.30B18.66N/AN/A$15.10 per share15.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biogen Inc. stock logo
BIIB
Biogen
$1.63B$10.1313.098.031.0615.07%14.03%8.32%7/30/2025 (Estimated)
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$719.92M-$3.40N/AN/AN/A-27.37%-3.94%-3.41%8/4/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$8.73N/AN/AN/A-105.67%-28.69%-21.94%7/30/2025 (Estimated)
Novozymes A/S stock logo
NVZMY
Novozymes A/S
$330.91M$1.5844.8833.141.34N/AN/AN/A8/21/2025 (Estimated)
Seagen Inc. stock logo
SGEN
Seagen
-$610.31M-$4.01N/AN/AN/A-32.61%-28.06%-20.92%N/A

Latest BIIB, SGEN, MRNA, BNTX, and NVZMY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q1 2025
Biogen Inc. stock logo
BIIB
Biogen
$3.26$3.02-$0.24$1.64$2.25 billion$2.43 billion
5/1/2025Q1 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.92-$2.52+$0.40-$2.52$130.35 million$108.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Novozymes A/S stock logo
NVZMY
Novozymes A/S
$0.761.07%N/A48.10%N/A
Seagen Inc. stock logo
SGEN
Seagen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biogen Inc. stock logo
BIIB
Biogen
0.27
1.44
1.01
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.01
10.18
10.02
Moderna, Inc. stock logo
MRNA
Moderna
N/A
4.22
4.14
Novozymes A/S stock logo
NVZMY
Novozymes A/S
0.14
1.73
1.06
Seagen Inc. stock logo
SGEN
Seagen
N/A
2.67
2.12

Institutional Ownership

CompanyInstitutional Ownership
Biogen Inc. stock logo
BIIB
Biogen
87.93%
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
15.52%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Novozymes A/S stock logo
NVZMY
Novozymes A/S
0.03%
Seagen Inc. stock logo
SGEN
Seagen
84.26%

Insider Ownership

CompanyInsider Ownership
Biogen Inc. stock logo
BIIB
Biogen
0.18%
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
19.20%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Novozymes A/S stock logo
NVZMY
Novozymes A/S
N/A
Seagen Inc. stock logo
SGEN
Seagen
25.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,605146.53 million146.26 millionOptionable
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
6,772240.39 million194.24 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800386.74 million344.20 millionOptionable
Novozymes A/S stock logo
NVZMY
Novozymes A/S
10,582468.30 millionN/ANot Optionable
Seagen Inc. stock logo
SGEN
Seagen
3,256187.70 million139.08 millionOptionable

Recent News About These Companies

Merck in "advanced talks" for $40bn Seagen bid; report
Seagen posts breast cancer win ahead of Pfizer takeover
Is Merck planning a $30bn-plus move for Seagen?
Pfizer raises guidance as COVID franchise drives Q3 beat
Franklin Biotechnology Discovery C
Seagen wins Enhertu patent dispute with Daiichi Sankyo
Pfizer: Turning The Corner (Rating Upgrade)
HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn
MRNA Feb 2024 64.000 put
MRNA Feb 2024 77.000 call
MRNA Feb 2024 67.000 put

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biogen stock logo

Biogen NASDAQ:BIIB

$132.62 -0.57 (-0.42%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$132.87 +0.25 (+0.18%)
As of 07/3/2025 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BioNTech stock logo

BioNTech NASDAQ:BNTX

$109.64 +1.39 (+1.28%)
Closing price 07/3/2025 03:53 PM Eastern
Extended Trading
$109.64 0.00 (0.00%)
As of 07/3/2025 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Moderna stock logo

Moderna NASDAQ:MRNA

$30.47 +0.19 (+0.63%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$30.50 +0.03 (+0.08%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Novozymes A/S stock logo

Novozymes A/S OTCMKTS:NVZMY

$70.91 -0.71 (-0.99%)
As of 07/3/2025 12:58 PM Eastern

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services. In addition, the company provides dishwashing, softener, microbial and medical cleaning services. Further, it provides corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; warm water species, recirculating aquaculture system; animal health and nutrition solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions. Additionally, the company provides carbon capture, leather and textiles solutions; enzyme solutions, including corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; warm water species and recirculating aquaculture system solutions; human health solutions, comprising brain, oral, protective and immune, and gastrointestinal health solutions; ethanol, biodiesel, renewable diesel, education, wastewater, and sewage sludge, and renewable diesel solutions; agriculture and industry, biogas food waste, food waste, biocatalysis, cell culture, diagnostics, enzyme, and biogas solutions. Furthermore, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novozymes A/S was founded in 1925 and is based in Bagsvaerd, Denmark.

Seagen stock logo

Seagen NASDAQ:SGEN

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.